1. Home
  2. URGN vs WABC Comparison

URGN vs WABC Comparison

Compare URGN & WABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$21.96

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Westamerica Bancorporation

WABC

Westamerica Bancorporation

HOLD

Current Price

$48.97

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
URGN
WABC
Founded
2004
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
URGN
WABC
Price
$21.96
$48.97
Analyst Decision
Strong Buy
Hold
Analyst Count
8
2
Target Price
$28.50
$52.00
AVG Volume (30 Days)
998.4K
116.9K
Earning Date
11-06-2025
01-15-2026
Dividend Yield
N/A
3.76%
EPS Growth
N/A
N/A
EPS
N/A
4.59
Revenue
$96,516,000.00
$264,660,000.00
Revenue This Year
$27.96
N/A
Revenue Next Year
$123.02
N/A
P/E Ratio
N/A
$10.67
Revenue Growth
8.00
N/A
52 Week Low
$3.42
$42.00
52 Week High
$30.00
$56.83

Technical Indicators

Market Signals
Indicator
URGN
WABC
Relative Strength Index (RSI) 42.19 56.53
Support Level $21.74 $46.93
Resistance Level $30.00 $49.50
Average True Range (ATR) 1.56 1.19
MACD -0.72 0.10
Stochastic Oscillator 3.15 67.26

Price Performance

Historical Comparison
URGN
WABC

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About WABC Westamerica Bancorporation

Westamerica Bancorp is based in San Rafael, California. Westamerica Bancorporation runs a regional community bank and has approximately $7.5 billion in assets. The banks' net revenue is generated by net interest income. Deposit service charges make up the noninterest income sources. The bank focuses mostly on commercial clients, such as smaller businesses. Its footprint encompasses central and northern California, extending north of San Francisco to Mendocino and Lake counties, south to Kern County in central California and all the way east to Nevada County.

Share on Social Networks: